Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Capital Expenditures (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Capital Expenditures for 2 consecutive years, with $95000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 1483.33% to $95000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $518000.0 through Dec 2025, up 1338.89% year-over-year, with the annual reading at $518000.0 for FY2025, 1338.89% up from the prior year.
  • Capital Expenditures hit $95000.0 in Q4 2025 for Xilio Therapeutics, down from $401000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $401000.0 in Q2 2025 to a low of $6000.0 in Q4 2024.